Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis

Aim: to perform retrospective evaluation of tocilizumab (TCZ) treatment every 2 and 4 weeks. Patients and methods: 33 children with systemic juvenile idiopathic arthritis (sJIA) were observed. Results: children, who need TCZ treatment every 2 weeks had more severe sJIA course. Patients which were treated every 4 weeks had higher TCZ efficacy, no new cases of macrophage activation syndrome (MAS), lower frequency of organ involvement and relapses during TCZ treatment. In 5 (20,8%) children of this group the TCZ-free remission was achieved, and in 3/5 children total drug-free remission lasted the maximum 1085 days was reached. Only 1 children in 4 weeks group developed relapse which leaded to re-start of TCZ treatment with the same efficacy as at first. No patients, who were treated every 2 weeks experienced TCZ-free remission. Also 4 cases of MAS were detected in children who had MAS before the start of TCZ. In 3/4 TCZ was discontinued but in 1 MAS TCZ accompanied with corticosteroids was prolonged. No new MAS cases were detected during this study. Infusion reactions lead to TCZ discontinuation were in 9,1%. 1 death (3,0%) during the trial. Conclusions: we offered the set of clinical and laboratorial criteria of high and low risk patients who need TCZ treatment every 2 and 4 weeks consequently.

Key words: systemic juvenile idiopathic arthritis, interleukine-6, tocilizumab.

1. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun. Rev. 2012; 12 (1): 56–59.

2. Gurion R., Lehman T. J., Moorthy L. N. Systemic arthritis in children: a review of clinical presentation and treatment. Int. J. Inflamm. 2012; 2012: 271569. Epub.: 2011 Dec 25.

3. Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., Woo P., Nishimoto N., Yoshizaki K., Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.

4. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005; 201: 1479–1486.

5. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., Iwata N., Umebayashi H., Murata T., Miyoshi M., Tomiita M., Nishimoto N., Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371 (9617): 998–1006.

6. De Benedetti F., Brunner H. I., Ruperto N., Kenwright A., Wright S., Calvo I., Cuttica R., Ravelli A., Schneider R., Woo P., Wouters C., Xavier R., Zemel L., Baildam E., Burgos-Vargas R., Dolezalova P., Garay S. M., Merino R., Joos R., Grom A., Wulffraat N., Zuber Z., Zulian F., Lovell D., Martini A.; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367 (25): 2385–2395.

7. De Benedetti F. Tocilizumab for systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2013; 368 (13): 1256–1257.

8. Petty R. E., Southwood T. R., Manners P., Baum J., Glass D. N., Goldenberg J. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J. Rheumatol. 2004; 31: 390–392.

9. Woo P., Wilkinson N., Prieur A. M., Southwood T., Leone V., Livermore P., Wythe H., Thomson D., Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 2005; 7 (6): 1281–1288.

10. Maini R. N., Taylor P. C., Szechinski J., Pavelka K., Broll J., Balint G., Emery P., Raemen F., Petersen J., Smolen J., Thomson D., Kishimoto T; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54 (9): 2817–2829.

11. Imagawa T., Yokota S., Mori M., Miyamae T., Takei S., Imanaka H., Nerome Y., Iwata N., Murata T., Miyoshi M., Nishimoto N., Kishimoto T. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod. Rheumatol. 2012; 22 (1): 109–115.

12. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat. Clin. Pract. Rheumatol. 2006; 2: 28–34.

13. DeWitt E. M., Kimura Y., Beukelman T., Nigrovic P. A., Onel K., Prahalad S., Schneider R., Stoll M. L., Angeles-Han S., Milojevic D., Schikler K. N., Vehe R. K., Weiss J. E., Weiss P., Ilowite N. T., Wallace C. A. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Juvenile Idiopathic Arthritis DiseaseSpecific Research Committee of Childhood Arthritis Rheumatology and Research Alliance. Arthritis Care Res (Hoboken). 2012; 64 (7): 1001–1010.

14. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S., Delfino L., Ferlito F., Pelagatti M. A., Caroli F., Buoncompagni A., Viola S., Loy A., Sironi M., Vecchi A., Ravelli A., Martini A., Rubartelli A. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58 (5): 1505–1515.

15. Kessler E. A., Vora S. S., Verbsky J. W. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr. Rheumatol. Online J. 2012; 10 (1): 30.